期刊簡介 | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Cardiology in Review LetPub Score 5.1
50 ratings
Rate
Reputation 6.4 Influence 3.7 Speed 7.0 | ||||||||||||||||
期刊簡稱 | CARDIOL REV | ||||||||||||||||
ISSN | 1061-5377 | ||||||||||||||||
E-ISSN | 1538-4683 | ||||||||||||||||
h-index | 51 | ||||||||||||||||
CiteScore |
| ||||||||||||||||
自引率 (2023-2024) | 0.00%自引率趨勢 | ||||||||||||||||
掲載範囲 |
| ||||||||||||||||
官方網站 | http://journals.lww.com/cardiologyinreview/pages/default.aspx | ||||||||||||||||
在線稿件提交 | https://www.editorialmanager.com/CIR | ||||||||||||||||
開放訪問 | No | ||||||||||||||||
出版商 | Lippincott Williams and Wilkins Ltd. | ||||||||||||||||
主題領域 | CARDIAC & CARDIOVASCULAR SYSTEMS | ||||||||||||||||
出版國/地區 | UNITED STATES | ||||||||||||||||
發行頻率 | 四半期刊行 | ||||||||||||||||
創刊年 | 1993 | ||||||||||||||||
每年文章數 | 46每年文章數趨勢 | ||||||||||||||||
黃金OA百分比 | 4.35% | ||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q3
| ||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1061-5377%5BISSN%5D | ||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: >12 Week(s), or Invited contributions | ||||||||||||||||
競爭力 * | 來自作者的數據: | ||||||||||||||||
參考鏈接 |
| ||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[Cardiology in Review] 的評論 | 撰寫評論 |
作者: 雾都含芙 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-07-24 15:12:38 評論於 Fellow authors, the review process is fast, isn't it?(0) 讚! | 雾都含芙 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 21:02:30 評論於 The abstract of a paper helps readers connect all the different parts of the paper, so it is important to avoid too many detailed descriptions(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 18:13:20 評論於 Each sentence in the abstract should provide maximum information as concisely as possible. The length of the abstract generally does not exceed 300 words. The beginning of the abstract should present the most important information (but not repeat the title). It can be the purpose or topic, as well as the result or conclusion. The abstract should include no more than 4 or 5 of the most important points, results, or implications(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 上清雨真 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-28 18:45:12 評論於 How can I make reviewers understand my research just by reading the abstract?(0) 讚! | 上清雨真 |
作者: 破戒阳平 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-28 15:02:09 評論於 How to reduce the abstract to the required word count by the journal? Which part should be deleted?(0) 讚! | 破戒阳平 |
作者: 是绮艳吖 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-11-19 23:53:56 評論於 Review speed: 6.0 Experience sharing: Submitted a review article, under review for 4 months, ultimately rejected, stating that my writing was too complex for the reviewers to make a decision(0) 讚! | 是绮艳吖 |
作者: 是绮艳吖 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-11-19 13:21:34 評論於 My paper was rejected after four months of review(0) 讚! | 是绮艳吖 |
作者: 沛容氏 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-11-19 11:43:23 評論於 I got a desk reject, yours should have been reviewed externally(0) 讚! | 沛容氏 |
作者: 沛容氏 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-11-16 13:56:37 評論於 Refusal to return in 2 days(0) 讚! | 沛容氏 |
作者: 是你的屠维呀 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2018-06-07 12:37:53 評論於 This is the first time I found this magazine. Does the magazine specialize in reviews?(0) 讚! | 是你的屠维呀 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-07-18 21:56:32 評論於 Although there haven't been any major changes this year, we'll see what happens in the future(0) 讚! | 凌霄高洁 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2012-11-28 21:25:05 評論於 Can we score 3 points next year? Let's discuss(0) 讚! | 凌霄高洁 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2011-06-29 20:50:47 評論於 Bullish, it is expected to break through 3 points if it rises again tomorrow(0) 讚! | 凌霄高洁 |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us